#Asia

Listen to personal tales from the global urban AIDS response, including reports from five U.S. cities.

Ninety-six–week data from the Phase I/IIa trial showed the mosaic vaccine was safe and offered a broad and durable immune response.

The study of mixed-HIV-status gay couples prompted the CDC to conclude that undetectable people have effectively no risk of passing on HIV.

U.K. public health officials have expressed great concern over this latest sign of evolution of the sexually transmitted infection.

These rates are driven in large part by hepatitis B and C.

HIV scientists and advocates are waging a powerful war against the global epidemic.

Highlights from the research presented at the 9th International AIDS Society Conference on HIV Science in Paris.

But the median CD4 count at treatment start is below 350, which means work is needed to catch up to World Health Organization guidelines.

The country is urged to offer treatment to everyone who has HIV regardless of CD4 count; most cases are among young men.

The vaccine prompted a robust immune response against HIV in those without the virus; now researchers hope to move it into advanced trials.

The agency has issued an urgent call to nations to implement steps to ward off this threat to progress in fighting the epidemic.

For the first time, more than half of people with HIV are taking meds. The analysis also shows troubling trends in the former Soviet region.

Scientists were also able to synthesize the newfound compound, saving the trouble of relying on plant growth for any production.

Numerous low- and middle-income nations have taken great strides in getting their HIV populations on antiretrovirals more promptly.

With a major new HIV vaccine trial under way, cautious optimism is stirring that the vaccine will prove effective enough for a rollout.

Despite all the excited talk of ending the epidemic, annual global HIV infection rates have not declined for a decade.